Risk Factors and Outcomes for Patients with Bloodstream Infection Due to Acinetobacter baumannii-calcoaceticus Complex

Identifying patients at risk for bloodstream infection (BSI) due to Acinetobacter baumannii-Acinetobacter calcoaceticus complex (ABC) and providing early appropriate therapy are critical for improving patient outcomes. A retrospective matched case-control study was conducted to investigate the risk...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Antimicrobial agents and chemotherapy 2014-08, Vol.58 (8), p.4630-4635
Hauptverfasser: CHOPRA, Teena, MARCHAIM, Dror, KAYE, Keith S, JOHNSON, Paul C, AWALI, Reda A, DOSHI, Hardik, CHALANA, Indu, DAVIS, Naomi, ZHAO, Jing J, POGUE, Jason M, PARMAR, Sapna
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 4635
container_issue 8
container_start_page 4630
container_title Antimicrobial agents and chemotherapy
container_volume 58
creator CHOPRA, Teena
MARCHAIM, Dror
KAYE, Keith S
JOHNSON, Paul C
AWALI, Reda A
DOSHI, Hardik
CHALANA, Indu
DAVIS, Naomi
ZHAO, Jing J
POGUE, Jason M
PARMAR, Sapna
description Identifying patients at risk for bloodstream infection (BSI) due to Acinetobacter baumannii-Acinetobacter calcoaceticus complex (ABC) and providing early appropriate therapy are critical for improving patient outcomes. A retrospective matched case-control study was conducted to investigate the risk factors for BSI due to ABC in patients admitted to the Detroit Medical Center (DMC) between January 2006 and April 2009. The cases were patients with BSI due to ABC; the controls were patients not infected with ABC. Potential risk factors were collected 30 days prior to the ABC-positive culture date for the cases and 30 days prior to admission for the controls. A total of 245 case patients were matched with 245 control patients. Independent risk factors associated with BSI due to ABC included a Charlson's comorbidity score of ≥ 3 (odds ratio [OR], 2.34; P = 0.001), a direct admission from another health care facility (OR, 4.63; P < 0.0001), a prior hospitalization (OR, 3.11; P < 0.0001), the presence of an indwelling central venous line (OR, 2.75; P = 0.011), the receipt of total parenteral nutrition (OR, 21.2; P < 0.0001), the prior receipt of β-lactams (OR, 3.58; P < 0.0001), the prior receipt of carbapenems (OR, 3.18; P = 0.006), and the prior receipt of chemotherapy (OR, 15.42; P < 0.0001). The median time from the ABC-positive culture date to the initiation of the appropriate antimicrobial therapy was 2 days (interquartile range [IQR], 1 to 3 days). The in-hospital mortality rate was significantly higher among case patients than among control patients (OR, 3.40; P < 0.0001). BSIs due to ABC are more common among critically ill and debilitated institutionalized patients, who are heavily exposed to health care settings and invasive devices.
doi_str_mv 10.1128/AAC.02441-14
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4135982</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1560109898</sourcerecordid><originalsourceid>FETCH-LOGICAL-a524t-2e7cb83587f848870dfc878baac183e1da3d728c1882fe7cab084b3a1b892c2a3</originalsourceid><addsrcrecordid>eNp1kUFv1DAQRi0Eokvhxhn5ggQSKbbjJOML0rKlUKlSEYKzNXEc6pLYW9sp8O_rskuBAydr5Kc3mu8j5ClnR5wLeL1eb46YkJJXXN4jK84UVG2j2vtkxVjbVhKYPCCPUrpkZW4Ue0gOhATFGiVX5PqTS9_oCZocYqLoB3q-ZBNmm-gYIv2I2VmfE_3u8gV9O4UwpBwtzvTUj9ZkFzw9XizNga6N8zaHvqhspD0uM3rvXGVwMgGNzc4siW7CvJ3sj8fkwYhTsk_27yH5cvLu8-ZDdXb-_nSzPquwETJXwnamh7qBbgQJ0LFhNNBBj2g41JYPWA-dgDKAGAuLPQPZ18h7UMIIrA_Jm513u_SzHUy5JeKkt9HNGH_qgE7_--Pdhf4arrXkdaNAFMGLvSCGq8WmrGeXjJ0m9DYsSfOmZbeRKyjoqx1qYkgp2vFuDWf6tipdqtK_qtJcFvzlDsc0C30ZluhLEv9jn_19xp34d48FeL4HMJXAx4jeuPSHg1Zx6GR9A5isqzY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1560109898</pqid></control><display><type>article</type><title>Risk Factors and Outcomes for Patients with Bloodstream Infection Due to Acinetobacter baumannii-calcoaceticus Complex</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>CHOPRA, Teena ; MARCHAIM, Dror ; KAYE, Keith S ; JOHNSON, Paul C ; AWALI, Reda A ; DOSHI, Hardik ; CHALANA, Indu ; DAVIS, Naomi ; ZHAO, Jing J ; POGUE, Jason M ; PARMAR, Sapna</creator><creatorcontrib>CHOPRA, Teena ; MARCHAIM, Dror ; KAYE, Keith S ; JOHNSON, Paul C ; AWALI, Reda A ; DOSHI, Hardik ; CHALANA, Indu ; DAVIS, Naomi ; ZHAO, Jing J ; POGUE, Jason M ; PARMAR, Sapna</creatorcontrib><description><![CDATA[Identifying patients at risk for bloodstream infection (BSI) due to Acinetobacter baumannii-Acinetobacter calcoaceticus complex (ABC) and providing early appropriate therapy are critical for improving patient outcomes. A retrospective matched case-control study was conducted to investigate the risk factors for BSI due to ABC in patients admitted to the Detroit Medical Center (DMC) between January 2006 and April 2009. The cases were patients with BSI due to ABC; the controls were patients not infected with ABC. Potential risk factors were collected 30 days prior to the ABC-positive culture date for the cases and 30 days prior to admission for the controls. A total of 245 case patients were matched with 245 control patients. Independent risk factors associated with BSI due to ABC included a Charlson's comorbidity score of ≥ 3 (odds ratio [OR], 2.34; P = 0.001), a direct admission from another health care facility (OR, 4.63; P < 0.0001), a prior hospitalization (OR, 3.11; P < 0.0001), the presence of an indwelling central venous line (OR, 2.75; P = 0.011), the receipt of total parenteral nutrition (OR, 21.2; P < 0.0001), the prior receipt of β-lactams (OR, 3.58; P < 0.0001), the prior receipt of carbapenems (OR, 3.18; P = 0.006), and the prior receipt of chemotherapy (OR, 15.42; P < 0.0001). The median time from the ABC-positive culture date to the initiation of the appropriate antimicrobial therapy was 2 days (interquartile range [IQR], 1 to 3 days). The in-hospital mortality rate was significantly higher among case patients than among control patients (OR, 3.40; P < 0.0001). BSIs due to ABC are more common among critically ill and debilitated institutionalized patients, who are heavily exposed to health care settings and invasive devices.]]></description><identifier>ISSN: 0066-4804</identifier><identifier>EISSN: 1098-6596</identifier><identifier>DOI: 10.1128/AAC.02441-14</identifier><identifier>PMID: 24890594</identifier><identifier>CODEN: AACHAX</identifier><language>eng</language><publisher>Washington, DC: American Society for Microbiology</publisher><subject>Acinetobacter ; Acinetobacter baumannii ; Acinetobacter baumannii - drug effects ; Acinetobacter baumannii - pathogenicity ; Acinetobacter baumannii - physiology ; Acinetobacter calcoaceticus ; Acinetobacter calcoaceticus - drug effects ; Acinetobacter calcoaceticus - pathogenicity ; Acinetobacter calcoaceticus - physiology ; Acinetobacter Infections ; Acinetobacter Infections - drug therapy ; Acinetobacter Infections - etiology ; Acinetobacter Infections - microbiology ; Acinetobacter Infections - mortality ; Adult ; Aged ; Anti-Bacterial Agents - adverse effects ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antineoplastic Agents - adverse effects ; Bacteremia ; Bacteremia - drug therapy ; Bacteremia - etiology ; Bacteremia - microbiology ; Bacteremia - mortality ; Bacterial diseases ; Bacterial sepsis ; Biological and medical sciences ; Case-Control Studies ; Catheters, Indwelling - adverse effects ; Epidemiology and Surveillance ; Female ; Hospital Mortality ; Hospitalization - statistics &amp; numerical data ; Human bacterial diseases ; Humans ; Infectious diseases ; Male ; Medical sciences ; Middle Aged ; Parenteral Nutrition - adverse effects ; Pharmacology. Drug treatments ; Retrospective Studies ; Risk Factors ; Survival Analysis</subject><ispartof>Antimicrobial agents and chemotherapy, 2014-08, Vol.58 (8), p.4630-4635</ispartof><rights>2015 INIST-CNRS</rights><rights>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</rights><rights>Copyright © 2014, American Society for Microbiology. All Rights Reserved. 2014 American Society for Microbiology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a524t-2e7cb83587f848870dfc878baac183e1da3d728c1882fe7cab084b3a1b892c2a3</citedby><cites>FETCH-LOGICAL-a524t-2e7cb83587f848870dfc878baac183e1da3d728c1882fe7cab084b3a1b892c2a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135982/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135982/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=28691874$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24890594$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CHOPRA, Teena</creatorcontrib><creatorcontrib>MARCHAIM, Dror</creatorcontrib><creatorcontrib>KAYE, Keith S</creatorcontrib><creatorcontrib>JOHNSON, Paul C</creatorcontrib><creatorcontrib>AWALI, Reda A</creatorcontrib><creatorcontrib>DOSHI, Hardik</creatorcontrib><creatorcontrib>CHALANA, Indu</creatorcontrib><creatorcontrib>DAVIS, Naomi</creatorcontrib><creatorcontrib>ZHAO, Jing J</creatorcontrib><creatorcontrib>POGUE, Jason M</creatorcontrib><creatorcontrib>PARMAR, Sapna</creatorcontrib><title>Risk Factors and Outcomes for Patients with Bloodstream Infection Due to Acinetobacter baumannii-calcoaceticus Complex</title><title>Antimicrobial agents and chemotherapy</title><addtitle>Antimicrob Agents Chemother</addtitle><addtitle>Antimicrob Agents Chemother</addtitle><description><![CDATA[Identifying patients at risk for bloodstream infection (BSI) due to Acinetobacter baumannii-Acinetobacter calcoaceticus complex (ABC) and providing early appropriate therapy are critical for improving patient outcomes. A retrospective matched case-control study was conducted to investigate the risk factors for BSI due to ABC in patients admitted to the Detroit Medical Center (DMC) between January 2006 and April 2009. The cases were patients with BSI due to ABC; the controls were patients not infected with ABC. Potential risk factors were collected 30 days prior to the ABC-positive culture date for the cases and 30 days prior to admission for the controls. A total of 245 case patients were matched with 245 control patients. Independent risk factors associated with BSI due to ABC included a Charlson's comorbidity score of ≥ 3 (odds ratio [OR], 2.34; P = 0.001), a direct admission from another health care facility (OR, 4.63; P < 0.0001), a prior hospitalization (OR, 3.11; P < 0.0001), the presence of an indwelling central venous line (OR, 2.75; P = 0.011), the receipt of total parenteral nutrition (OR, 21.2; P < 0.0001), the prior receipt of β-lactams (OR, 3.58; P < 0.0001), the prior receipt of carbapenems (OR, 3.18; P = 0.006), and the prior receipt of chemotherapy (OR, 15.42; P < 0.0001). The median time from the ABC-positive culture date to the initiation of the appropriate antimicrobial therapy was 2 days (interquartile range [IQR], 1 to 3 days). The in-hospital mortality rate was significantly higher among case patients than among control patients (OR, 3.40; P < 0.0001). BSIs due to ABC are more common among critically ill and debilitated institutionalized patients, who are heavily exposed to health care settings and invasive devices.]]></description><subject>Acinetobacter</subject><subject>Acinetobacter baumannii</subject><subject>Acinetobacter baumannii - drug effects</subject><subject>Acinetobacter baumannii - pathogenicity</subject><subject>Acinetobacter baumannii - physiology</subject><subject>Acinetobacter calcoaceticus</subject><subject>Acinetobacter calcoaceticus - drug effects</subject><subject>Acinetobacter calcoaceticus - pathogenicity</subject><subject>Acinetobacter calcoaceticus - physiology</subject><subject>Acinetobacter Infections</subject><subject>Acinetobacter Infections - drug therapy</subject><subject>Acinetobacter Infections - etiology</subject><subject>Acinetobacter Infections - microbiology</subject><subject>Acinetobacter Infections - mortality</subject><subject>Adult</subject><subject>Aged</subject><subject>Anti-Bacterial Agents - adverse effects</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Bacteremia</subject><subject>Bacteremia - drug therapy</subject><subject>Bacteremia - etiology</subject><subject>Bacteremia - microbiology</subject><subject>Bacteremia - mortality</subject><subject>Bacterial diseases</subject><subject>Bacterial sepsis</subject><subject>Biological and medical sciences</subject><subject>Case-Control Studies</subject><subject>Catheters, Indwelling - adverse effects</subject><subject>Epidemiology and Surveillance</subject><subject>Female</subject><subject>Hospital Mortality</subject><subject>Hospitalization - statistics &amp; numerical data</subject><subject>Human bacterial diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Parenteral Nutrition - adverse effects</subject><subject>Pharmacology. Drug treatments</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Survival Analysis</subject><issn>0066-4804</issn><issn>1098-6596</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kUFv1DAQRi0Eokvhxhn5ggQSKbbjJOML0rKlUKlSEYKzNXEc6pLYW9sp8O_rskuBAydr5Kc3mu8j5ClnR5wLeL1eb46YkJJXXN4jK84UVG2j2vtkxVjbVhKYPCCPUrpkZW4Ue0gOhATFGiVX5PqTS9_oCZocYqLoB3q-ZBNmm-gYIv2I2VmfE_3u8gV9O4UwpBwtzvTUj9ZkFzw9XizNga6N8zaHvqhspD0uM3rvXGVwMgGNzc4siW7CvJ3sj8fkwYhTsk_27yH5cvLu8-ZDdXb-_nSzPquwETJXwnamh7qBbgQJ0LFhNNBBj2g41JYPWA-dgDKAGAuLPQPZ18h7UMIIrA_Jm513u_SzHUy5JeKkt9HNGH_qgE7_--Pdhf4arrXkdaNAFMGLvSCGq8WmrGeXjJ0m9DYsSfOmZbeRKyjoqx1qYkgp2vFuDWf6tipdqtK_qtJcFvzlDsc0C30ZluhLEv9jn_19xp34d48FeL4HMJXAx4jeuPSHg1Zx6GR9A5isqzY</recordid><startdate>20140801</startdate><enddate>20140801</enddate><creator>CHOPRA, Teena</creator><creator>MARCHAIM, Dror</creator><creator>KAYE, Keith S</creator><creator>JOHNSON, Paul C</creator><creator>AWALI, Reda A</creator><creator>DOSHI, Hardik</creator><creator>CHALANA, Indu</creator><creator>DAVIS, Naomi</creator><creator>ZHAO, Jing J</creator><creator>POGUE, Jason M</creator><creator>PARMAR, Sapna</creator><general>American Society for Microbiology</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>5PM</scope></search><sort><creationdate>20140801</creationdate><title>Risk Factors and Outcomes for Patients with Bloodstream Infection Due to Acinetobacter baumannii-calcoaceticus Complex</title><author>CHOPRA, Teena ; MARCHAIM, Dror ; KAYE, Keith S ; JOHNSON, Paul C ; AWALI, Reda A ; DOSHI, Hardik ; CHALANA, Indu ; DAVIS, Naomi ; ZHAO, Jing J ; POGUE, Jason M ; PARMAR, Sapna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a524t-2e7cb83587f848870dfc878baac183e1da3d728c1882fe7cab084b3a1b892c2a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Acinetobacter</topic><topic>Acinetobacter baumannii</topic><topic>Acinetobacter baumannii - drug effects</topic><topic>Acinetobacter baumannii - pathogenicity</topic><topic>Acinetobacter baumannii - physiology</topic><topic>Acinetobacter calcoaceticus</topic><topic>Acinetobacter calcoaceticus - drug effects</topic><topic>Acinetobacter calcoaceticus - pathogenicity</topic><topic>Acinetobacter calcoaceticus - physiology</topic><topic>Acinetobacter Infections</topic><topic>Acinetobacter Infections - drug therapy</topic><topic>Acinetobacter Infections - etiology</topic><topic>Acinetobacter Infections - microbiology</topic><topic>Acinetobacter Infections - mortality</topic><topic>Adult</topic><topic>Aged</topic><topic>Anti-Bacterial Agents - adverse effects</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Bacteremia</topic><topic>Bacteremia - drug therapy</topic><topic>Bacteremia - etiology</topic><topic>Bacteremia - microbiology</topic><topic>Bacteremia - mortality</topic><topic>Bacterial diseases</topic><topic>Bacterial sepsis</topic><topic>Biological and medical sciences</topic><topic>Case-Control Studies</topic><topic>Catheters, Indwelling - adverse effects</topic><topic>Epidemiology and Surveillance</topic><topic>Female</topic><topic>Hospital Mortality</topic><topic>Hospitalization - statistics &amp; numerical data</topic><topic>Human bacterial diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Parenteral Nutrition - adverse effects</topic><topic>Pharmacology. Drug treatments</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Survival Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CHOPRA, Teena</creatorcontrib><creatorcontrib>MARCHAIM, Dror</creatorcontrib><creatorcontrib>KAYE, Keith S</creatorcontrib><creatorcontrib>JOHNSON, Paul C</creatorcontrib><creatorcontrib>AWALI, Reda A</creatorcontrib><creatorcontrib>DOSHI, Hardik</creatorcontrib><creatorcontrib>CHALANA, Indu</creatorcontrib><creatorcontrib>DAVIS, Naomi</creatorcontrib><creatorcontrib>ZHAO, Jing J</creatorcontrib><creatorcontrib>POGUE, Jason M</creatorcontrib><creatorcontrib>PARMAR, Sapna</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Antimicrobial agents and chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CHOPRA, Teena</au><au>MARCHAIM, Dror</au><au>KAYE, Keith S</au><au>JOHNSON, Paul C</au><au>AWALI, Reda A</au><au>DOSHI, Hardik</au><au>CHALANA, Indu</au><au>DAVIS, Naomi</au><au>ZHAO, Jing J</au><au>POGUE, Jason M</au><au>PARMAR, Sapna</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risk Factors and Outcomes for Patients with Bloodstream Infection Due to Acinetobacter baumannii-calcoaceticus Complex</atitle><jtitle>Antimicrobial agents and chemotherapy</jtitle><stitle>Antimicrob Agents Chemother</stitle><addtitle>Antimicrob Agents Chemother</addtitle><date>2014-08-01</date><risdate>2014</risdate><volume>58</volume><issue>8</issue><spage>4630</spage><epage>4635</epage><pages>4630-4635</pages><issn>0066-4804</issn><eissn>1098-6596</eissn><coden>AACHAX</coden><abstract><![CDATA[Identifying patients at risk for bloodstream infection (BSI) due to Acinetobacter baumannii-Acinetobacter calcoaceticus complex (ABC) and providing early appropriate therapy are critical for improving patient outcomes. A retrospective matched case-control study was conducted to investigate the risk factors for BSI due to ABC in patients admitted to the Detroit Medical Center (DMC) between January 2006 and April 2009. The cases were patients with BSI due to ABC; the controls were patients not infected with ABC. Potential risk factors were collected 30 days prior to the ABC-positive culture date for the cases and 30 days prior to admission for the controls. A total of 245 case patients were matched with 245 control patients. Independent risk factors associated with BSI due to ABC included a Charlson's comorbidity score of ≥ 3 (odds ratio [OR], 2.34; P = 0.001), a direct admission from another health care facility (OR, 4.63; P < 0.0001), a prior hospitalization (OR, 3.11; P < 0.0001), the presence of an indwelling central venous line (OR, 2.75; P = 0.011), the receipt of total parenteral nutrition (OR, 21.2; P < 0.0001), the prior receipt of β-lactams (OR, 3.58; P < 0.0001), the prior receipt of carbapenems (OR, 3.18; P = 0.006), and the prior receipt of chemotherapy (OR, 15.42; P < 0.0001). The median time from the ABC-positive culture date to the initiation of the appropriate antimicrobial therapy was 2 days (interquartile range [IQR], 1 to 3 days). The in-hospital mortality rate was significantly higher among case patients than among control patients (OR, 3.40; P < 0.0001). BSIs due to ABC are more common among critically ill and debilitated institutionalized patients, who are heavily exposed to health care settings and invasive devices.]]></abstract><cop>Washington, DC</cop><pub>American Society for Microbiology</pub><pmid>24890594</pmid><doi>10.1128/AAC.02441-14</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0066-4804
ispartof Antimicrobial agents and chemotherapy, 2014-08, Vol.58 (8), p.4630-4635
issn 0066-4804
1098-6596
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4135982
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
subjects Acinetobacter
Acinetobacter baumannii
Acinetobacter baumannii - drug effects
Acinetobacter baumannii - pathogenicity
Acinetobacter baumannii - physiology
Acinetobacter calcoaceticus
Acinetobacter calcoaceticus - drug effects
Acinetobacter calcoaceticus - pathogenicity
Acinetobacter calcoaceticus - physiology
Acinetobacter Infections
Acinetobacter Infections - drug therapy
Acinetobacter Infections - etiology
Acinetobacter Infections - microbiology
Acinetobacter Infections - mortality
Adult
Aged
Anti-Bacterial Agents - adverse effects
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antineoplastic Agents - adverse effects
Bacteremia
Bacteremia - drug therapy
Bacteremia - etiology
Bacteremia - microbiology
Bacteremia - mortality
Bacterial diseases
Bacterial sepsis
Biological and medical sciences
Case-Control Studies
Catheters, Indwelling - adverse effects
Epidemiology and Surveillance
Female
Hospital Mortality
Hospitalization - statistics & numerical data
Human bacterial diseases
Humans
Infectious diseases
Male
Medical sciences
Middle Aged
Parenteral Nutrition - adverse effects
Pharmacology. Drug treatments
Retrospective Studies
Risk Factors
Survival Analysis
title Risk Factors and Outcomes for Patients with Bloodstream Infection Due to Acinetobacter baumannii-calcoaceticus Complex
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T21%3A55%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risk%20Factors%20and%20Outcomes%20for%20Patients%20with%20Bloodstream%20Infection%20Due%20to%20Acinetobacter%20baumannii-calcoaceticus%20Complex&rft.jtitle=Antimicrobial%20agents%20and%20chemotherapy&rft.au=CHOPRA,%20Teena&rft.date=2014-08-01&rft.volume=58&rft.issue=8&rft.spage=4630&rft.epage=4635&rft.pages=4630-4635&rft.issn=0066-4804&rft.eissn=1098-6596&rft.coden=AACHAX&rft_id=info:doi/10.1128/AAC.02441-14&rft_dat=%3Cproquest_pubme%3E1560109898%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1560109898&rft_id=info:pmid/24890594&rfr_iscdi=true